Monday, June 23, 2025 6/23/2025

Identification of Melanoma Brain Metastasis Tumor Biomarkers

Award Number: R01CA167967
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2013
PERIOD OF PERFORMANCE END DATE: 02/28/2019

Group Awards By:

View Award Description

Identification of Melanoma Brain Metastasis Tumor Biomarkers - DESCRIPTION (provided by applicant): Due to the escalating incidence rate of melanoma in the USA and its high frequency to metastasize to the brain, melanoma brain metastasis (MBM) poses an increasingly significant clinical problem. In the absence of predictive biomarkers for MBM, early recognition and effective management of MBM remain inadequate to the detriment of the nation's healthcare economy and patients' quality of life. We will identify genomic and epigenomic aberrations that are signatures of MBM. We will then develop and verify these molecular aberrations as predictive molecular MBM biomarker signature(s) of stage III and IV melanomas for high-risk of MBM occurrence. Our main hypothesis is that specific genomic and epigenomic biomarkers can be identified as signatures of MBM and utilized for stage III and early stage IV melanoma metastasis for MBM occurrence. The specific Aims are based on our strong preliminary studies on genomic and epigenomic aberrations identified in MBM. The Specific Aims are as follows: Aim I. Identify and develop a signature panel of MBM genomic biomarkers that can be used as predictive biomarkers in stage III and IV melanoma for MBM occurrence. Single-nucleotide polymorphism (SNP) will be used to identify copy number variations (CNV) for losses and gains as predictive biomarkers using customized quantitative PCR assays. Prioritized MBM genomic biomarkers will then be assessed as predictors of MBM occurrence. Aim II. Identify and develop a signature panel of epigenomic MBM biomarkers that can be used as predictive biomarkers in stage III and early stage IV for MBM occurrence. Methylation array and quantitative methylation-specific PCR assays have been used to screen and identify biomarker signatures of MBM. These predictive MBM epigenomic biomarkers will then be developed and analyzed by optimized quantitative methylation-specific PCR assays. Prioritized MBM epigenomic biomarkers will then be assessed as predictors of MBM occurrence. Aim III. Verify a MBM predictive signature(s) of genomic and/or epigenomic MBM biomarkers for stage III and IV metastasis. The optimal MBM biomarker signature panel identified in Aims I and II will be tested in patients with stage III and IV metastases, respectivey, for their ability to predict MBM occurrence using phase III multicenter clinical trial patients who have undergone surgical resection to be rendered disease-free. The studies will verify high-risk stage III and IV patients' melanoma subtypes developing into MBM, identification of new targets for therapy, and identification of MBM molecular signatures.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = -$103,134 )
2019	2017	JOHN WAYNE CANCER INSTITUTE	2200 SANTA MONICA BLVD	SANTA MONICA	CA	90404	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	5	7/1/2019	NON-COMPETING CONTINUATION	-$103,134
														Subtotal = -$103,134

Issue Date FY: 2017 ( Subtotal = $382,423 )
2017	2017	JOHN WAYNE CANCER INSTITUTE	2200 SANTA MONICA BLVD	SANTA MONICA	CA	90404	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	5	3/3/2017	NON-COMPETING CONTINUATION	$344,180
2017	2017	JOHN WAYNE CANCER INSTITUTE	2200 SANTA MONICA BLVD	SANTA MONICA	CA	90404	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	001	5	6/7/2017	NON-COMPETING CONTINUATION	$38,243
														Subtotal = $382,423

Issue Date FY: 2016 ( Subtotal = $382,423 )
2016	2016	JOHN WAYNE CANCER INSTITUTE	2200 SANTA MONICA BOULEVARD	SANTA MONICA	CA	90404	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	4	2/17/2016	EXTENSION WITH OR WITHOUT FUNDS	$382,423
														Subtotal = $382,423

Issue Date FY: 2015 ( Subtotal = $382,423 )
2015	2015	JOHN WAYNE CANCER INSTITUTE	2200 SANTA MONICA BOULEVARD	SANTA MONICA	CA	90404	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	3	4/1/2015	NON-COMPETING CONTINUATION	$382,423
														Subtotal = $382,423

Issue Date FY: 2014 ( Subtotal = $370,950 )
2014	2014	JOHN WAYNE CANCER INSTITUTE	2200 SANTA MONICA BOULEVARD	SANTA MONICA	CA	90404	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	2	3/5/2014	NON-COMPETING CONTINUATION	$344,180
2014	2014	JOHN WAYNE CANCER INSTITUTE	2200 SANTA MONICA BOULEVARD	SANTA MONICA	CA	90404	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	001	2	5/2/2014	NON-COMPETING CONTINUATION	$26,770
														Subtotal = $370,950

Issue Date FY: 2013 ( Subtotal = $382,423 )
2013	2013	JOHN WAYNE INSTITUTE FOR CANCER TREATMENT & RSCH	2200 SANTA MONICA BOULEVARD	SANTA MONICA	CA	90404	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	001	1	6/28/2013	NEW	$95,606
2013	2013	JOHN WAYNE INSTITUTE FOR CANCER TREATMENT & RSCH	2200 SANTA MONICA BOULEVARD	SANTA MONICA	CA	90404	LOS ANGELES	USA	Cancer Detection and Diagnosis Research	000	1	2/20/2013	NEW	$286,817
														Subtotal = $382,423

Grand Total All Awards = $1,797,508

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Identification of Melanoma Brain Metastasis Tumor Biomarkers

Award Number: R01CA167967

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2013

PERIOD OF PERFORMANCE END DATE: 02/28/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer